Alkeus Pharmaceuticals
The Director, Clinical Operations leads and manages global, late-stage pivotal clinical trials in alignment with corporate objectives and regulatory guidelines. This role oversees CROs and vendors to ensure successful study execution, including site activation, enrollment, and monitoring. The position serves as the primary operational point of contact across internal teams to drive cohesive study execution and ensure compliance with quality standards.
Headquarters
Cambridge, Massachusetts, United States
Company Size
11-50 employees
Founded
2010
Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, guided by the tagline "Transformation in Sight." The company's unique therapeutic approach targets the prevention of toxic vitamin A dimer accumulation in the retina, without modulating the visual cycle, to address conditions such as Stargardt disease and geographic atrophy secondary to age-related macular degeneration. Its lead oral investigational therapy, gildeuretinol, is being evaluated in clinical studies including the TEASE and SAGA trials.
Alkeus Pharmaceuticals Announces Presentation of Investigational Oral Gildeuretinol Data During the 49th Annual Meeting of the Macula Society Being Held February 25-28
3 weeks ago
Alkeus Pharmaceuticals to Present Corporate Update at the 44th Annual J.P. Morgan Healthcare Conference
Jan 8, 2026
Favorable safety data supports Alkeus' oral gildeuretinol for dry AMD
May 9, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Alkeus Pharmaceuticals .
20% above the average for this role
Companies announce presentations at upcoming 2025 ARVO Annual Meeting
Apr 30, 2025